Cagrilintide + Semaglutide Peptide Therapy
Benefits, Side Effects, Cost & Protocols
CagriSema is a combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) being developed by Novo Nordisk. The dual mechanism targets both amylin and GLP-1 pathways for potentially greater weight loss than either agent alone.
Clinically Reviewed
Reviewed by Alex Evans, PharmD, MBA · Updated October 2026
Evidence-Based
Sourced from FDA, PubMed & ClinicalTrials.gov · View sources
Who Is Cagrilintide + Semaglutide Best For?
How Cagrilintide + Semaglutide Works
Combines amylin-mediated satiety and gastric effects with GLP-1 receptor activation for dual metabolic pathway targeting.
Cagrilintide + Semaglutide FAQ
What is CAGRILINTIDE + SEMAGLUTIDE?
A dual-action combination of Cagrilintide (amylin analog) and Semaglutide (GLP-1 agonist) being researched for enhanced weight management effects through complementary mechanisms.
How does CAGRILINTIDE + SEMAGLUTIDE work?
Combines amylin-mediated satiety and gastric effects with GLP-1 receptor activation for dual metabolic pathway targeting.
Is CAGRILINTIDE + SEMAGLUTIDE legal to buy?
CAGRILINTIDE + SEMAGLUTIDE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy CAGRILINTIDE + SEMAGLUTIDE?
CAGRILINTIDE + SEMAGLUTIDE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does CAGRILINTIDE + SEMAGLUTIDE belong to?
CAGRILINTIDE + SEMAGLUTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.
What are the research benefits of CAGRILINTIDE + SEMAGLUTIDE?
CAGRILINTIDE + SEMAGLUTIDE has been studied for: Enhanced weight management, Dual mechanism approach, Appetite control. Dual-action blend targeting multiple metabolic pathways.
Key Studies
80 total on PubMed0Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey WT, Blüher M, Osorto Contreras CK et al
N Engl J MedPhase 3
Cagrilintide-semaglutide reduced body weight by 20.4% vs 3.0% with placebo.
Cagrilintide-semaglutide reduced body weight by 20.4% vs 3.0% with placebo
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies MJ, Bajaj HS, Broholm C et al
N Engl J MedPhase 3
Cagrilintide-semaglutide reduced body weight by 13.7% vs 3.4% with placebo in type 2 diabetes.
Cagrilintide-semaglutide reduced body weight by 13.7% vs 3.4% with placebo in type 2 diabetes
Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials
El-Sheikh M, Sillassen CDB, Wisborg FD et al
BMJ Open
Protocol for systematic review of cardiovascular effects of incretin-based drugs in heart failure patients
Incretin-based therapies for the treatment of obesity-related diseases
Cagrilintide + Semaglutide News
Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications - PR Newswire
PR Newswire · 4 months ago
Weight loss: New drug CagriSema leads to 14% weight loss in trial - MedicalNewsToday
MedicalNewsToday · 8 months ago
Novo Nordisk’s CagriSema outperforms Ozempic in Phase III trial - Clinical Trials Arena
Clinical Trials Arena · 8 months ago
The Peptide Surge: Counseling Guidance on GLP-1s, Compounded Therapies, and What Patients Want to Know - Pharmacy Times
Pharmacy Times · 3 months ago
What Is CagriSema? Weight Loss Results, Availability, & More - Ro
Ro · 3 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Ready to explore Cagrilintide + Semaglutide with a provider?
Take our 2-minute quiz to get matched with a board-certified provider specializing in Cagrilintide + Semaglutide.
Take the Quiz →